至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Delivery of microRNA-33 Antagomirs by Mesoporous Silica Nanoparticles to Ameliorate Lipid Metabolic Disorders

Front Pharmacol. 2020; 
Yaoye Tao, Shengjun Xu, Jianguo Wang, Li Xu, Chenzhi Zhang, Kangchen Chen, Zhengxing Lian, Junbin Zhou, Haiyang Xie, Shusen Zheng, Xiao Xu
Products/Services Used Details Operation
Molecular Biology Reagents … Samples of the proteins were run on 8%–12% SDS-PAGE gels for immunoblotting. The primary antibodies used were SREBF1 (1:1000, Proteintech, USA), ABCA1 (1:1000, Abcam, UK), and β-actin (1:5000, Genscript, China) … Get A Quote

摘要

Lipid metabolic disorders have become a major global public health concern. Fatty liver and dyslipidemia are major manifestations of these disorders. Recently, MicroRNA-33 (miR-33), a post-transcriptional regulator of genes involved in cholesterol efflux and fatty acid oxidation, has been considered as a good therapeutic target for these disorders. However, the traditional methods of gene therapy impede their further clinical transformation into a mature treatment system. To counter this problem, in this study we used mesoporous silica nanoparticles (MSNs) as nanocarriers to deliver miR-33 antagomirs developing nanocomposites miR-MSNs. We observed that the hepatocellular uptake of miR-33 antagomirs increased by... More

关键词

dyslipidemia, lipid metabolic disorder, mesoporous silica nanoparticles, miR-33, non-alcoholic fatty liver disease